Anixa Biosciences (ANIX) vs Cumberland Pharmaceuticals (CPIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 193.5% versus a loss of 43.8%. Over five years, CPIX leads with a +161.9% price change compared with -38.7% for ANIX. Cumberland Pharmaceuticals is the larger company by market cap ($87.6 million vs $84.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | CPIX |
|---|---|---|
| Share price | $2.44 | $5.84 |
| Market cap | $84.82M | $87.57M |
| 1-day change | -6.15% | -7.30% |
| YTD return | -21.79% | +46.73% |
| 1-year return | -43.78% | +193.47% |
| 5-year return | -38.69% | +161.88% |
| Forward P/E | — | 41.71 |
| EPS (TTM) | $-0.32 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $44.52M |
| Revenue growth (YoY) | — | +17.57% |
| Net income (latest FY) | $-10.93M | $-2.84M |
| Gross margin | — | 85.02% |
| Operating margin | — | -6.27% |
| Net margin | — | -6.37% |
| 52-week high | $5.46 | $9.28 |
| 52-week low | $2.32 | $2.00 |
| Distance from 52-week high | -55.31% | -37.07% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +296.31% | — |
| Average volume | 282.29K | 114.52K |
| Shares outstanding | 34.76M | 15.00M |
| Employees | 4 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed ANIX by 237.2 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
ANIX vs CPIX FAQ
Which is bigger, Anixa Biosciences or Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $87.57M compared with $84.82M for Anixa Biosciences (ANIX).
Which stock has performed better over the past year, ANIX or CPIX?
CPIX returned +193.47% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Cumberland Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.